Adjuvants and Inactivated Polio Vaccine: a Systematic Review

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2012 Oct 9

PMID 23041122

Citations 23

Authors

Jennifer Hawken

Stephanie B Troy

Affiliations

Soon will be listed here.

Abstract

Poliomyelitis is nearing universal eradication; in 2011, there were 650 cases reported globally. When wild polio is eradicated, global oral polio vaccine (OPV) cessation followed by use of universal inactivated polio vaccine (IPV) is believed to be the safest vaccination strategy as IPV does not mutate or run the risk of vaccine derived outbreaks that OPV does. However, IPV is significantly more expensive than OPV. One strategy to make IPV more affordable is to reduce the dose by adding adjuvants, compounds that augment the immune response to the vaccine. No adjuvants are currently utilized in stand-alone IPV; however, several have been explored over the past six decades. From aluminum, used in many licensed vaccines, to newer and more experimental adjuvants such as synthetic DNA, a diverse group of compounds has been assessed with varying strengths and weaknesses. This review summarizes the studies to date evaluating the efficacy and safety of adjuvants used with IPV.

Citing Articles

Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges-A Narrative Review.

Hodel K, Sampaio Dotto Fiuza B, Conceicao R, Aleluia A, Pitanga T, Moraes Dos Santos Fonseca L Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931474 PMC: 11206969. DOI: 10.3390/ph17060807.

Intratumor childhood vaccine-specific CD4 T-cell recall coordinates antitumor CD8 T cells and eosinophils.

Brown M, Beasley G, McKay Z, Yang Y, Desjardins A, Randazzo D J Immunother Cancer. 2023; 11(4).

PMID: 37072349 PMC: 10124325. DOI: 10.1136/jitc-2022-006463.

The Integrated Consideration of Vaccine Platforms, Adjuvants, and Delivery Routes for Successful Vaccine Development.

Kozak M, Hu J Vaccines (Basel). 2023; 11(3).

PMID: 36992279 PMC: 10055765. DOI: 10.3390/vaccines11030695.

Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.

Kumar P, Bird C, Holland D, Joshi S, Volkin D Hum Vaccin Immunother. 2022; 18(7):2154100.

PMID: 36576132 PMC: 9891683. DOI: 10.1080/21645515.2022.2154100.

Immunogenicity and Reactogenicity in Q Fever Vaccine Development.

Fratzke A, van Schaik E, Samuel J Front Immunol. 2022; 13:886810.

PMID: 35693783 PMC: 9177948. DOI: 10.3389/fimmu.2022.886810.

References

KRAVCHENKO A, Tsetlin E, Omelchenko T . [Rational method of producing sera with high titers of virus neutralizing antibodies]. Zh Mikrobiol Epidemiol Immunobiol. 1977; (1):41-5. View

Hartmann G, Krieg A . Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000; 164(2):944-53. DOI: 10.4049/jimmunol.164.2.944. View

AUERSWALD W, JUERGENSSEN O . [On the problem of antibody formation against poliomyelitis in small children. Studies on the effect of an adjuvant vaccine with antigen components against poliomyelitis, diphtheria, pertussis and tetanus]. Wien Med Wochenschr. 1960; 110:646-8. View

Jenkins H, Aylward R, Gasasira A, Donnelly C, Mwanza M, Corander J . Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010; 362(25):2360-9. DOI: 10.1056/NEJMoa0910074. View

Ghendon Y, Markushin S, Krivtsov G, Akopova I . Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol. 2008; 153(5):831-7. DOI: 10.1007/s00705-008-0047-4. View

Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman D . CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011; 10(4):499-511. PMC: 3108434. DOI: 10.1586/erv.10.174. View

Ghendon Y, Markushin S, Akopova I, Koptiaeva I, Krivtsov G . Chitosan as an adjuvant for poliovaccine. J Med Virol. 2011; 83(5):847-52. DOI: 10.1002/jmv.22030. View

Durando P, Icardi G, Ansaldi F . MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther. 2010; 10(4):639-51. DOI: 10.1517/14712591003724662. View

Baldwin S, Fox C, Pallansch M, Coler R, Reed S, Friede M . Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine. 2010; 29(4):644-9. DOI: 10.1016/j.vaccine.2010.11.043. View

10.

Landi S, Penney C, Shah P, HART F, Campbell J, Cucakovich N . Adjuvanticity of stearyl tyrosine on inactivated poliovirus vaccine. Vaccine. 1986; 4(2):99-104. DOI: 10.1016/0264-410x(86)90046-0. View

11.

HENNEBERG G, Drescher J, GODGLUECK G, GRUETZNER L . Immunogenic activity of aqueous and aluminum oxide adsorbed poliovirus vaccine in Macaca mulatta. Am J Hyg. 1962; 75:44-55. DOI: 10.1093/oxfordjournals.aje.a120233. View

12.

SALK J, Lewis L, Youngner J, Bennett B . The use of adjuvants to facilitate studies on the immunologic classification of poliomyelitis viruses. Am J Hyg. 1951; 54(2):157-73. DOI: 10.1093/oxfordjournals.aje.a119474. View

13.

Nelson K, Janssen J, Troy S, Maldonado Y . Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine. 2011; 30(2):121-5. DOI: 10.1016/j.vaccine.2011.11.018. View

14.

Tan L, Weissig V, Gregoriadis G . Comparison of the immune response against polio peptides covalently-surface-linked to and internally-entrapped in liposomes. Asian Pac J Allergy Immunol. 1991; 9(1):25-30. View

15.

SUREAU P, Fabre P, NGaro S, Butor S, Poulougou M, RELYVELD E . [Simultaneous testanus and poliomyelitis vaccination of infants in a tropical environment]. Bull World Health Organ. 1977; 55(6):739-46. PMC: 2366703. View

16.

Vogel F, Powell M . A compendium of vaccine adjuvants and excipients. Pharm Biotechnol. 1995; 6:141-228. DOI: 10.1007/978-1-4615-1823-5_7. View

17.

Lemire J . Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem. 1992; 49(1):26-31. DOI: 10.1002/jcb.240490106. View

18.

Nathanson N, Kew O . From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010; 172(11):1213-29. PMC: 2991634. DOI: 10.1093/aje/kwq320. View

19.

He Q, Mitchell A, Johnson S, Morcol T, Bell S . Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol. 2000; 7(6):899-903. PMC: 95982. DOI: 10.1128/CDLI.7.6.899-903.2000. View

20.

Gupta R, Siber G . Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals. 1994; 22(1):53-63. DOI: 10.1006/biol.1994.1008. View